혈액학 시장 : 시장 인사이트, 경쟁 환경 및 시장 예측(-2030년)

Hematology Market By Type (Instruments [Hematology Analyzers, Hematology Cell Counters, Flow Cytometers, Coagulation Analyzers, Others], Kits And Reagents), By Application (Cardiovascular Diseases, Auto-Immune Diseases, Cancer, Diabetes Mellitus, Infectious Diseases, Others), By Modality (Clinical Laboratory Devices, Point Of Care Devices), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising incidence of blood-related disorders and rapid technological developmental activities

Global Hematology Market was valued at USD 2.13 Billion in 2023, growing at a CAGR of 7.98% during the forecast period from 2024 to 2030 to reach USD 3.38 Billion by 2030. The Hematology market is witnessing positive growth owing to the rising prevalence of blood and its related disorders, a surge in the research and development activities in product development, increasing incidences of the aging population who are susceptible to these diseases. Moreover, the growing popularity and expanding awareness of minimally invasive interventions, further pushed for the demand of these devices, thereby contributing to the growth of the Hematology market during the forecast period from 2024-2030.

Hematology Market Dynamics:

The Hematology market is witnessing a growth in product demand owing to various reasons. The major factor responsible is the rising prevalence of blood and related disorders such as anemia, blood cancers, hemorrhagic conditions, thalassemia, and blood infections.

Chronic blood disorders have a significant impact on the health and quality of life of patients and their families. They can cause pain, loss of normal functioning, depression, and anxiety, financial burden, long-term hospitalization, and even death. Therefore, to properly treat and manage chronic blood disorders, Hematology devices are required. These devices help to detect clotting deficiencies, measure coagulation pathways speed, thrombin levels, and are also used to monitor the effects of drugs on whole blood. Since their use is quite extensive and offers wide applications in blood disorders, thus the demand for these devices will grow, which in turn is expected to drive the Global Hematology market.

According to the Centers for Disease Control and Prevention 2020, people with hemophilia have unique risk factors that may lead them to heart disease as their life expectancy increases, such as infusion of factor concentrates and infection with HIV. Owing to the growing burden of lifestyle-associated and chronic blood disorders across the globe, the Hematology market has been rising significantly. Similarly, as per Haemophilia Foundation Australia 2022, Haemophilia occurs in 1 in 6,000-10,000 males internationally. According to the same statistics, in Australia, there are more than 3,000 people diagnosed with varying degrees of severity of Haemophilia.

In addition, key players operating in the market are focusing on developing advanced technologically based Hematology devices and reagents. For instance, in March 2019, HORIBA Medical launched a new Yumizen GDDi 2 (D-Dimer) reagent kit in its hemostasis instrument range, which includes the compact Yumizen G200 coagulation analyzer. The kit offers a key measurement and reference exclusion test for the diagnosis of deep vein thrombosis (DVT) and pulmonary embolism (PE). It can also be used for monitoring the progress and effectiveness of treatment of Disseminated Intravascular Coagulation (DIC). Thus, such development by players may help in contributing to patient management that will augment the demand for Global Hematology and will drive the market growth during the forecasted period from 2024-2030.

Moreover, it is predicted that the rising number of elderly patients would transform healthcare delivery and create a larger demand for Hematology. As per the recent survey, Global Population Aging 2020 Report (United Nations, 2020), the aging population tends to grow at an alarming pace. In 2020, there were around 727 million individuals in the world aged 65 years or older. By 2050, the figure for such patients is expected to double and reach 1.5 billion by 2050. Since the aging population is more prone to blood disorders, therefore it will give rise to more demand for Hematology devices, which will boost the Hematology market. Thus, all these factors are projected to drive the growth of the market for Hematology.

However, the high cost and unavailability of skilled professionals may be certain limiting factors of the Hematology market growth.

The ongoing Coronavirus disease 2019 (COVID-19) pandemic has slightly positively impacted the market for Hematology as hospital admissions for COVID -19 patients were at maximum priority and Hematology was used for corona-infected patients in order to provide supportive treatments. This resulted in the increased demand for Hematology during the pandemic. Moreover, the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape post pandemically made the resumption of regular healthcare services, which kept the demand for these products on course in the Hematology market.

Hematology Market Segment Analysis:

Hematology Market By Type (Instruments [Hematology Analyzers, Hematology Cell Counters, Flow Cytometers, Coagulation Analyzers, Others], Kits and Reagents), By Application (Cardiovascular Diseases, Auto-immune Diseases, Cancer, Diabetes Mellitus, Infectious Diseases, Others), By Modality (Clinical Laboratory Devices, Point of Care Devices), By End-User (Hospitals & Clinics, Diagnostic Laboratories, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Type segment of the Hematology market, Coagulation Analyzers are estimated to hold a higher share in the Hematology market during the forecast period (2024-2030). This can be attributed to the specific features associated with these devices.

The rapid growth of this segment can be attributed to the minimal interaction which drastically reduces the chances of infections, errors, rapid precision which ensures reproducibility, reduced personnel to do the task, and most importantly, a large number of samples that can be processed at the same time.

The advantage associated with Coagulation Analyzers is that they can be used to measure a coagulation pathway speed, as well as thrombolin and thromboplastin levels in as low as a few minutes. A coagulation analyzer is specifically designed to handle a large number of patients, permitting the storage of up to 600 patient tests per well, which further increases their demand, thereby driving the growth of the overall Hematology market.

Additionally, a new development in the product lines and new product launches are bolstering the segment growth of the Hematology market during the forecasted period.

North America is expected to dominate the overall Hematology Market:

Among all the regions, North America is expected to account for the largest share in the Global Hematology market. This domination is owing to the rising prevalence of chronic blood diseases, increased incidence of these disorders in the aging population, and improved product launches are expected to aid in the growth of the North America Hematology Market.

The cases of blood disease are rising constantly and these cases promote the need for use of Hematology in disease treatment in North America. For instance, as per the National Hemophilia Foundation 2022, between 30,000- 33,000 people are living with hemophilia in the US.

Additionally, according to CDC 2020, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year in the United States.

Moreover, according to the Canadian Chronic Disease Surveillance System, heart disease is the leading cause of disability-adjusted life years (DALYs) lost due to ill-health, disability, or early death worldwide.

Furthermore, the increased emphasis on product development activities and the high interest of device manufacturers in accessing local markets through collaborative agreements further aid in the growth of the regional markets for Hematology. For instance, in March 2022, PixCell Medical, innovator of rapid hematology testing solutions at the point of care, announced its exclusive distribution agreement with Katalyst Diagnostics, a new division of Katalyst Laboratories, to distribute HemoScreen. HemoScreen is the only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care (POC) use.

These kinds of partnerships in the local markets may drive the product demand in the market. Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Hematology market during the forecast period.

Hematology Market Key Players:

Some of the key market players operating in the Hematology market include Sysmex Corporation, Danaher, Nihon Kohden Corporation, Siemens Healthcare GmbH, Abbott, Boule Diagnostics, Bio-Rad Laboratories, Inc., Biosystems S.A., Diatron, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Erba Mannheim, Ortho Clinical Diagnostics, Abaxis, Heska Corporation, F. Hoffmann-La Roche Ltd, Horiba Ltd., Neomedica, Thermo Fisher Scientific, Agilent, and others.

Recent Developmental Activities in the Hematology Market:

In February 2022, Horiba Medical announced that its new generation of the Microsemi CRP hematology analyzer, the Microsemi CRP LC-767G, has received CE marking. The new analyzer is more compact and has enhanced software and network connectivity with higher memory. It also includes a new parameter, the Granulocytes-to-Lymphocytes Ratio.

In January 2022, PixCell Medical announced that it has signed a distribution agreement for its HemoScreen Hematology Analyzer in Sweden with Triolab. HemoScreen is a portable, point-of-care complete blood count analyzer that uses disposable cartridges that include all necessary reagents and provides results from a single drop of blood from a fingerstick.

In July 2020, Sysmex launched next-generation fully automated blood coagulation analyzers CN-6000 and CN-3000 in the EMEA region.

Key Takeaways from the Hematology Market Report Study

• Market size analysis for current Hematology market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Hematology market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global Hematology market.
• Various opportunities available for the other competitor in the Hematology market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current Hematology market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Hematology market growth in the coming future?

Target Audience who can be benefited from this Hematology Market Report Study

• Hematology products providers
• Research organizations and consulting companies
• Hematology-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Hematology
• Various End-users who want to know more about the Hematology market and latest technological developments in the Hematology market.

Frequently Asked Questions for the Hematology Market:

1. What is Hematology?

Hematology is the branch of medicine related to the study of the cause, prognosis, treatment, and prevention of diseases related to blood.

2. What is the market for Global Hematology?

Global Hematology Market was valued at USD 2.13 Billion in 2023, growing at a CAGR of 7.98% during the forecast period from 2024 to 2030 to reach USD 3.38 Billion by 2030.

3. What are the drivers for the Global Hematology Market?

The Hematology market is witnessing a positive market growth owing to the rising prevalence of blood and its related disorders, a surge in the research and development activities in product development, increasing incidences of the aging population who are susceptible to these diseases. Moreover, the growing popularity and expanding awareness of minimally invasive interventions, further pushed for the demand of these devices, thereby contributing to the growth of the Hematology market during the forecast period from 2024-2030.

4. Who are the key players operating in the Global Hematology Market?

Some of the key market players operating in the Hematology market include Sysmex Corporation, Danaher, Nihon Kohden Corporation, Siemens Healthcare GmbH, Abbott, Boule Diagnostics, Bio-Rad Laboratories, Inc., Biosystems S.A., Diatron, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Erba Mannheim, Ortho Clinical Diagnostics, Abaxis, Heska Corporation, F. Hoffmann-La Roche Ltd, Horiba Ltd., Neomedica, Thermo Fisher Scientific, Agilent, and others.

5. Which region has the highest share in Hematology Market?

North America is expected to hold the highest share in the revenue in the Hematology market during the forecast period. This domination is owing to the rising prevalence of chronic blood diseases, increased incidence of these disorders in the aging population, and improved product launches are expected to aid in the growth of the North America Hematology Market.

Table of Contents

1.Hematology Market Report Introduction

2.Hematology Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment
• 2.4. Financial Benchmarking

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Hematology Market Key Factors Analysis

• 4.1. Hematology Market Drivers
  • 4.1.1. The Rising Prevalence of Blood and its Related Disorders
  • 4.1.2. A Surge in the Research and Development Activities in Product Development
  • 4.1.3. Increasing Incidences of the Aging Population who are Susceptible to these Diseases
  • 4.1.4. The Growing Popularity and Expanding Awareness of Minimally Invasive Interventions
• 4.2. Hematology Market Restraints and Challenges
  • 4.2.1. High Cost
  • 4.2.2. Unavailability of Skilled Professionals
• 4.3. Hematology Market Opportunities
  • 4.3.1. The Rise in Investment By Market Players For Technological Development
  • 4.3.2. Targeting Emerging Markets for Product Launches

5. Hematology Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Hematology Market

7. Hematology Market Layout

• 7.1. By Type
  • 7.1.1. Instruments
    • 7.1.1.1. Hematology Analyzers
    • 7.1.1.2. Hematology Cell Counters
    • 7.1.1.3. Flow Cytometers
    • 7.1.1.4. Coagulation Analyzers
    • 7.1.1.5. Others
  • 7.1.2. Kits and Reagents
• 7.2. By Application
  • 7.2.1. Cardiovascular Diseases
  • 7.2.2. Auto-immune Diseases
  • 7.2.3. Cancer
  • 7.2.4. Diabetes Mellitus
  • 7.2.5. Infectious Diseases
  • 7.2.6. Others
• 7.3. By Modality
  • 7.3.1. Clinical Laboratory Devices
  • 7.3.2. Point of Care Devices
• 7.4. By End User
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Diagnostic Laboratories
  • 7.4.3. Others
• 7.5. By Geography
  • 7.5.1. North America
    • 7.5.1.1. North America Hematology Market, by Country
    • 7.5.1.1.1. United States
    • 7.5.1.1.2. Canada
    • 7.5.1.1.3. Mexico
  • 7.5.2. Europe
    • 7.5.2.1. Europe Hematology Market, by Country
    • 7.5.2.1.1. France
    • 7.5.2.1.2. Germany
    • 7.5.2.1.3. United Kingdom
    • 7.5.2.1.4. Italy
    • 7.5.2.1.5. Spain
    • 7.5.2.1.6. Russia
    • 7.5.2.1.7. Rest of Europe
  • 7.5.3. Asia-Pacific
    • 7.5.3.1. Asia-Pacific Hematology Market, by Country
    • 7.5.3.1.1. China
    • 7.5.3.1.2. Japan
    • 7.5.3.1.3. India
    • 7.5.3.1.4. Australia
    • 7.5.3.1.5. South Korea
    • 7.5.3.1.6. Rest of Asia Pacific
  • 7.5.4. Rest of the World (RoW)
    • 7.5.4.1. RoW Hematology Market, by Region
    • 7.5.4.1.1. Middle East
    • 7.5.4.1.2. Africa
    • 7.5.4.1.3. South America

8. Hematology Market Global Company Share Analysis - Key 3-5 Companies

9. Hematology Market Company and Product Profiles

• 9.1 Sysmex Corporation
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. Danaher
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Nihon Kohden Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Siemens Healthcare GmbH
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. Abbott
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Boule Diagnostics
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. Bio-Rad Laboratories, Inc.
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Biosystems S.A.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Diatron
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. EKF Diagnostics
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Shenzhen Mindray Bio-Medical Electronics Co.
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. Erba Mannheim
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Ortho Clinical Diagnostics
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Abaxis
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Heska Corporation
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. F. Hoffmann-La Roche Ltd
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Horiba Ltd.
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Neomedica
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Thermo Fisher Scientific
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Agilent
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us